We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA
Read MoreHide Full Article
Alkermes Plc. (ALKS - Free Report) announced that after a pre-new drug application (NDA) meeting with the FDA, it plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia. Shares of the company were up 3.6% following the news.
Shares of Alkermes have declined 20.9% year to date compared with the industry’s decline of 0.2%.
Schizophrenia is a chronic, severe and disabling brain disorder. Bipolar disorder is a brain disorder that causes unusual shifts in a person's mood, energy and ability to function. The NDA for ALKS 3831, which is to be submitted in the fourth quarter of 2019, will include data from the completed ENLIGHTEN clinical development program in patients with schizophrenia and pharmacokinetic (PK) bridging data comparing ALKS 3831 with Eli Lilly & Co.’s (LLY - Free Report) Zyprexa (olanzapine).
The ALKS 3831 NDA will include data to support the treatment of manic or mixed episodes associated with bipolar I disorder as a monotherapy, or adjunct to lithium or valproate, and the maintenance treatment of bipolar I disorder. It will include additional data to support the treatment of schizophrenia.
Approval of the additional indication will help Alkermes gain access to a broader section of patients.
Other players in the schizophrenia treatment market include AstraZeneca plc's (AZN - Free Report) Seroquel XR, Johnson & Johnson's Risperdal Consta and Allergan’s Vraylar. Vraylar is also approved for the treatment of adults with major depressive episodes related to bipolar I disorder.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors. Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.
Image: Bigstock
Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA
Alkermes Plc. (ALKS - Free Report) announced that after a pre-new drug application (NDA) meeting with the FDA, it plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia. Shares of the company were up 3.6% following the news.
Shares of Alkermes have declined 20.9% year to date compared with the industry’s decline of 0.2%.
Schizophrenia is a chronic, severe and disabling brain disorder. Bipolar disorder is a brain disorder that causes unusual shifts in a person's mood, energy and ability to function. The NDA for ALKS 3831, which is to be submitted in the fourth quarter of 2019, will include data from the completed ENLIGHTEN clinical development program in patients with schizophrenia and pharmacokinetic (PK) bridging data comparing ALKS 3831 with Eli Lilly & Co.’s (LLY - Free Report) Zyprexa (olanzapine).
The ALKS 3831 NDA will include data to support the treatment of manic or mixed episodes associated with bipolar I disorder as a monotherapy, or adjunct to lithium or valproate, and the maintenance treatment of bipolar I disorder. It will include additional data to support the treatment of schizophrenia.
Approval of the additional indication will help Alkermes gain access to a broader section of patients.
Other players in the schizophrenia treatment market include AstraZeneca plc's (AZN - Free Report) Seroquel XR, Johnson & Johnson's Risperdal Consta and Allergan’s Vraylar. Vraylar is also approved for the treatment of adults with major depressive episodes related to bipolar I disorder.
Alkermes currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Alkermes plc Price
Alkermes plc price | Alkermes plc Quote
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors. Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.
See the 7 breakthrough stocks now>>